Stefan Schreiber Selected Research

vedolizumab

1/2022	Longitudinal monitoring of STAT3 phosphorylation and histologic outcome of tofacitinib therapy in patients with ulcerative colitis.
11/2021	Profile of patients with inflammatory bowel disease in conjunction with unmet needs and decision-making for choosing a new biologic therapy: a baseline analysis of the VEDOIBD-Study.
10/2021	Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From An Efficacy and Safety Study of Vedolizumab Intravenous Compared to Adalimumab Subcutaneous in Participants With Ulcerative Colitis (VARSITY).
1/2021	Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial.
1/2020	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. Reply.
11/2019	Monitoring of Vedolizumab Infusion Therapy (MOVE-IT) Response With Fecal Inflammation Markers, Ultrasound, and Trough Serum Level in Patients With Ulcerative Colitis: Protocol for a Multicentric, Prospective, Noninterventional Study.
1/2019	Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis.
1/2019	Vedolizumab is associated with changes in innate rather than adaptive immunity in patients with inflammatory bowel disease.
1/2019	Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.
9/2018	Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Stefan Schreiber Research Topics

Disease

99	Crohn Disease (Crohn's Disease) 11/2022 - 05/2002
62	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 05/2022 - 04/2002
57	Ulcerative Colitis 01/2022 - 03/2004
40	Inflammation (Inflammations) 01/2022 - 03/2004
27	Neoplasms (Cancer) 01/2022 - 09/2006
26	Infections 11/2022 - 09/2003
17	Necrosis 01/2021 - 06/2004
14	Obesity 01/2022 - 05/2007
14	Insulin Resistance 10/2021 - 01/2006
14	Colitis 12/2017 - 09/2008
10	Type 2 Diabetes Mellitus (MODY) 01/2022 - 10/2005
9	Rheumatoid Arthritis 01/2022 - 02/2005
8	Periodontitis 05/2022 - 11/2008
8	Sarcoidosis (Schaumann Disease) 04/2021 - 04/2005
8	Coronary Artery Disease (Coronary Atherosclerosis) 02/2015 - 08/2007
7	Psoriasis (Pustulosis Palmaris et Plantaris) 04/2022 - 06/2007
7	Atherosclerosis 01/2022 - 06/2007
7	Colorectal Neoplasms (Colorectal Cancer) 07/2020 - 01/2011
7	Cholelithiasis 06/2013 - 09/2006
7	Asthma (Bronchial Asthma) 04/2011 - 05/2003
6	Ankylosing Spondylitis 04/2022 - 06/2017
6	Hemorrhage 01/2022 - 07/2002
6	Body Weight (Weight, Body) 01/2022 - 11/2005
6	Carcinogenesis 01/2022 - 12/2005
6	Disease Progression 01/2016 - 03/2005
5	COVID-19 05/2022 - 10/2020
5	Heart Failure 12/2021 - 09/2007
5	Chronic Disease (Chronic Diseases) 01/2021 - 10/2004
5	Gallstones (Gallstone) 06/2013 - 11/2006
5	Sepsis (Septicemia) 03/2013 - 07/2002
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 08/2007
4	Weight Loss (Weight Reduction) 12/2021 - 06/2015
4	Atopic Dermatitis (Atopic Eczema) 01/2020 - 02/2008
4	Ulcer 01/2020 - 01/2012
4	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2018 - 08/2011
4	Sclerosing Cholangitis 01/2018 - 08/2010
4	Fibrosis (Cirrhosis) 01/2018 - 01/2011
4	Aggressive Periodontitis (Periodontosis) 10/2017 - 11/2008
4	Myocardial Infarction 12/2013 - 05/2007
4	Tuberculosis (Tuberculoses) 05/2012 - 02/2010
4	Genetic Predisposition to Disease (Genetic Predisposition) 06/2010 - 01/2005
4	Metabolic Syndrome (Dysmetabolic Syndrome X) 04/2010 - 03/2006
3	Proctitis 11/2022 - 01/2021
3	Wounds and Injuries (Trauma) 11/2022 - 05/2002
3	Rheumatic Diseases (Rheumatism) 05/2022 - 11/2019
3	Psoriatic Arthritis 04/2022 - 01/2019
3	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 01/2005

Drug/Important Bio-Agent (IBA)

33	Proteins (Proteins, Gene)FDA Link 01/2022 - 04/2003
25	Infliximab (Remicade)FDA Link 05/2022 - 10/2002
22	Pharmaceutical PreparationsIBA 11/2022 - 08/2007
19	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2021 - 05/2002
17	Certolizumab Pegol FDA Link 01/2021 - 09/2005
15	CytokinesIBA 05/2022 - 04/2003
15	Biological ProductsIBA 11/2021 - 10/2004
13	Monoclonal AntibodiesIBA 01/2022 - 06/2004
13	Biomarkers (Surrogate Marker)IBA 01/2021 - 11/2007
12	vedolizumabIBA 01/2022 - 01/2014
12	Adalimumab (Humira)FDA Link 01/2022 - 01/2007
12	Messenger RNA (mRNA)IBA 12/2017 - 09/2006
10	C-Reactive ProteinIBA 01/2022 - 03/2006
9	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 08/2005
9	Insulin (Novolin)FDA Link 10/2021 - 01/2006
9	Biosimilar PharmaceuticalsIBA 10/2021 - 01/2015
9	Tumor Necrosis Factor InhibitorsIBA 01/2021 - 01/2012
8	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 10/2004
8	DNA (Deoxyribonucleic Acid)IBA 01/2019 - 04/2002
7	Interleukin-6 (Interleukin 6)IBA 01/2022 - 08/2007
7	Anti-Bacterial Agents (Antibiotics)IBA 10/2019 - 03/2004
6	AntibodiesIBA 01/2022 - 03/2009
6	LipidsIBA 01/2022 - 07/2012
6	MicroRNAs (MicroRNA)IBA 11/2016 - 09/2010
6	Transcription Factors (Transcription Factor)IBA 01/2014 - 01/2009
5	IntegrinsIBA 07/2022 - 08/2013
5	Azathioprine (Imuran)FDA LinkGeneric 07/2022 - 06/2004
5	InterleukinsIBA 07/2022 - 06/2009
5	etrolizumabIBA 01/2022 - 08/2013
5	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2022 - 12/2009
5	EnzymesIBA 10/2020 - 11/2006
5	Mesalamine (Mesalazine)FDA LinkGeneric 09/2020 - 01/2007
5	Ribosomal DNA (rDNA)IBA 01/2018 - 12/2007
5	Dextrans (Dextran)FDA Link 01/2014 - 06/2009
5	Leucine (L-Leucine)FDA Link 12/2012 - 01/2005
5	NF-kappa B (NF-kB)IBA 02/2010 - 09/2007
4	CholesterolIBA 01/2022 - 11/2006
4	HLA Antigens (Human Leukocyte Antigens)IBA 01/2021 - 07/2020
4	Immunosuppressive Agents (Immunosuppressants)IBA 01/2021 - 06/2011
4	CT-P13IBA 01/2021 - 09/2016
4	Small Interfering RNA (siRNA)IBA 05/2017 - 02/2010
4	Interleukin-23 (Interleukin 23)IBA 01/2017 - 02/2009
4	DefensinsIBA 01/2015 - 01/2008
4	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2014 - 06/2009
4	Acetylmuramyl-Alanyl-IsoglutamineIBA 01/2012 - 12/2007
3	tofacitinibIBA 01/2022 - 01/2017
3	risankizumabIBA 01/2022 - 01/2017
3	LDL CholesterolIBA 01/2022 - 08/2008

Therapy/Procedure

66	Therapeutics 11/2022 - 07/2004
10	Biological Therapy 01/2022 - 09/2007
4	Aftercare (After-Treatment) 01/2020 - 10/2002
4	Liver Transplantation 01/2018 - 06/2013
4	Cholecystectomy 03/2013 - 09/2006